B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation

Transplantation Reviews

Volumn 24, Issue 4, 2010, Pages 207-221

  Parsons, Ronald F ^a   Vivek, Kumar ^a   Redfield, Robert R ^a   Migone, Thi Sau ^b   Cancro, Michael P ^a   Naji, Ali ^a   Noorchashm, Hooman ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; ALLOANTIGEN; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE RECEPTOR; BELIMUMAB; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; EPRATUZUMAB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MICRORNA; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIBODY SPECIFICITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL COMPARTMENTALIZATION; CELL SELECTION; CLINICAL TRIAL; DESENSITIZATION; GERMINAL CENTER; GRAFT REJECTION; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; RECEPTOR BINDING; REVIEW; SENSITIZATION; TARGET CELL; TRANSPLANTATION TOLERANCE;

EID: 77956989585     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.05.004     Document Type: Review

References (178)

1. Terasaki P.I., Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008, 86:377-383.
2. Colvin R.B. Pathology of chronic humoral rejection. Contrib Nephrol 2009, 162:75-86.
3. Colvin R.B., Smith R.N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005, 5:807-817.
4. Jordan S.C., Pescovitz M.D. Presensitization: the problem and its management. Clin J am Soc Nephrol 2006, 1:421-432.
5. Kirk A.D., Baldwin W.M., Cascalho M.I., Chong A.S., Sykes M., West L.J. American society of transplantation symposium on B cells in transplantation: harnessing humoral immunity from rodent models to clinical practice. Am J Transplant 2007, 7:1464-1470.
6. Terasaki P.I., Ozawa M., Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415.
7. Crowley J.E., Scholz J.L., Quinn W.J., et al. Homeostatic control of B lymphocyte subsets. Immunol Res 2008, 42:75-83.
8. Treml J.F., Hao Y., Stadanlick J.E., Cancro M.P. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009, 53:1-16.
9. Miller J.P., Stadanlick J.E., Cancro M.P. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006, 176:6405-6410.
10. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638.
11. Miosge L.A., Goodnow C.C. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol Cell Biol 2005, 83:318-335.
12. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
13. Allman D.M., Ferguson S.E., Cancro M.P., Peripheral B. Cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol 1992, 149:2533-2540.
14. Allman D.M., Ferguson S.E., Lentz V.M., Cancro M.P. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol 1993, 151:4431-4444.
15. Goodnow C.C., Sprent J., Fazekas de St Groth B., Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
16. Nossal G.J., Pike B.L. Evidence for the clonal abortion theory of B-lymphocyte tolerance. J Exp Med 1975, 141:904-917.
17. Lobo P.I., Spencer C., Simmons W.D., et al. Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc 2005, 37:3438-3440.
18. Louzoun Y., Friedman T., Luning Prak E., Litwin S., Weigert M. Analysis of B cell receptor production and rearrangement. Part I. Light chain rearrangement. Semin Immunol 2002, 14:169-190. [discussion 221-22].
19. Liu Y., Li L., Kumar K.R., et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J Immunol 2007, 179:1340-1352.
20. Verkoczy L.K., Martensson A.S., Nemazee D. The scope of receptor editing and its association with autoimmunity. Curr Opin Immunol 2004, 16:808-814.
21. Gay D., Saunders T., Camper S., Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993, 177:999-1008.
22. Kouskoff V., Lacaud G., Pape K., Retter M., Nemazee D. B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection. Proc Natl Acad Sci U S A 2000, 97:7435-7439.
23. Brahim F., Osmond D.G. Migration of bone marrow lymphocytes demonstrated by selective bone marrow labeling with thymidine-H3. Anat Rec 1970, 168:139-159.
24. Sprent J., Basten A. Circulating T and B lymphocytes of the mouse. II. Lifespan. Cell Immunol 1973, 7:40-59.
25. Nemazee D.A., Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989, 337:562-566.
26. Hartley S.B., Crosbie J., Brink R., Kantor A.B., Basten A., Goodnow C.C. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991, 353:765-769.
27. Erikson J., Radic M.Z., Camper S.A., Hardy R.R., Carmack C., Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 1991, 349:331-334.
28. Chen C., Radic M.Z., Erikson J., et al. Deletion and editing of B cells that express antibodies to DNA. J Immunol 1994, 152:1970-1982.
29. Murakami M., Tsubata T., Okamoto M., et al. Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature 1992, 357:77-80.
30. Norvell A., Mandik L., Monroe J.G. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol 1995, 154:4404-4413.
31. Russell D.M., Dembic Z., Morahan G., Miller J.F., Burki K., Nemazee D. Peripheral deletion of self-reactive B cells. Nature 1991, 354:308-311.
32. Cyster J.G., Hartley S.B., Goodnow C.C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994, 371:389-395.
33. Fulcher D.A., Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994, 179:125-134.
34. Noorchashm H., Bui A., Li H.L., et al. Characterization of anergic anti-DNA B cells: B cell anergy is a T cell-independent and potentially reversible process. Int Immunol 1999, 11:765-776.
35. Mandik-Nayak L., Bui A., Noorchashm H., Eaton A., Erikson J. Regulation of anti-double-stranded DNA B cells in nonautoimmune mice: localization to the T-B interface of the splenic follicle. J Exp Med 1997, 186:1257-1267.
36. Cancro M.P. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009, 9:657-661.
37. Stadanlick J.E., Kaileh M., Karnell F.G., et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008, 9:1379-1387.
38. Tsubata T., Wu J., Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993, 364:645-648.
39. Schwickert T.A., Alabyev B., Manser T., Nussenzweig M.C. Germinal center reutilization by newly activated B cells. J Exp Med 2009, 206:2907-2914.
40. Wardemann H., Nussenzweig M.C. B-cell self-tolerance in humans. Adv Immunol 2007, 95:83-110.
41. Fuller K.A., Kanagawa O., Nahm M.H. T cells within germinal centers are specific for the immunizing antigen. J Immunol 1993, 151:4505-4512.
42. Shokat K.M., Goodnow C.C. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 1995, 375:334-338.
43. Reed A.J., Riley M.P., Caton A.J. Virus-induced maturation and activation of autoreactive memory B cells. J Exp Med 2000, 192:1763-1774.
44. Treml L.S., Quinn W.J., Treml J.F., Scholz J.L., Cancro M.P. Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz) 2008, 56:153-164.
45. Yan M., Brady J.R., Chan B., et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001, 11:1547-1552.
46. Smith S.H., Cancro M.P. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J Immunol 2003, 170:5820-5823.
47. Lentz V.M., Cancro M.P., Nashold F.E., Hayes C.E. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J Immunol 1996, 157:598-606.
48. Batten M., Groom J., Cachero T.G., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
49. Mackay F., Woodcock S.A., Lawton P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
50. Moore P.A., Belvedere O., Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
51. Schneider P., MacKay F., Steiner V., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
52. Warnatz K., Salzer U., Rizzi M., et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A 2009, 106:13945-13950.
53. Kalled S.L. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005, 204:43-54.
54. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168:5993-5996.
55. Enzler T., Bonizzi G., Silverman G.J., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
56. Hatada E.N., Do R.K., Orlofsky A., et al. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol 2003, 171:761-768.
57. Woodland R.T., Fox C.J., Schmidt M.R., et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008, 111:750-760.
58. Day E.S., Cachero T.G., Qian F., et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005, 44:1919-1931.
59. Cao M., Chen L., Shan X.X., Zhang S.Q. Immunological effects of refolded human soluble BAFF synthesized in Escherichia coli on murine B lymphocytes in vitro and in vivo. Jpn J Physiol 2005, 55:221-227.
60. Hymowitz S.G., Patel D.R., Wallweber H.J., et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 2005, 280:7218-7227.
61. Dillon S.R., Gross J.A., Ansell S.M., Novak A.J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006, 5:235-246.
62. Bossen C., Cachero T.G., Tardivel A., et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
63. Gross J.A., Dillon S.R., Mudri S., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
64. Zekavat G., Rostami S.Y., Badkerhanian A., et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 2008, 181:8133-8144.
65. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
66. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
67. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006, 18:276-283.
68. Noorchashm H., Noorchashm N., Kern J., Rostami S.Y., Barker C.F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997, 46:941-946.
69. Quinn W.J., Noorchashm N., Crowley J.E., et al. Cutting edge: impaired transitional B cell production and selection in the nonobese diabetic mouse. J Immunol 2006, 176:7159-7164.
70. Kahn P., Ramanujam M., Bethunaickan R., et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008, 58:2824-2834.
71. Marino E., Villanueva J., Walters S., Liuwantara D., Mackay F., Grey S.T. CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 2009, 58:1568-1577.
72. Furie R., Stohl W., Ginzler E.M., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.
73. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 2008, 8:1805-1814.
74. Jacobi A.M., Huang A., Wang T., et al. Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.
75. Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial. Nat Rev Drug Discov 2009, 8:688.
76. MacLennan I.C., Gulbranson-Judge A., Toellner K.M., et al. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev 1997, 156:53-66.
77. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005, 5:230-242.
78. Han S., Zheng B., Takahashi Y., Kelsoe G. Distinctive characteristics of germinal center B cells. Semin Immunol 1997, 9:255-260.
79. Gore E.R., Gower J., Kurali E., et al. Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation. Toxicology 2004, 197:23-35.
80. Miller D.J., Hayes C.E. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur J Immunol 1991, 21:1123-1130.
81. Miller D.J., Hanson K.D., Carman J.A., Hayes C.E. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur J Immunol 1992, 22:373-379.
82. Rahman Z.S., Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol 2004, 173:6179-6188.
83. Benson M.J., Dillon S.R., Castigli E., et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008, 180:3655-3659.
84. Mantchev G.T., Cortesao C.S., Rebrovich M., Cascalho M., Bram R.J. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol 2007, 179:2282-2288.
85. Zarkhin V., Li L., Sarwal M. "To B or not to B?" B-cells and graft rejection. Transplantation 2008, 85:1705-1714.
86. Wood K.J. Is B cell tolerance essential for transplantation tolerance?. Transplantation 2005, 79(3 Suppl):S40-S42.
87. O'Connor B.P., Raman V.S., Erickson L.D., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-98.
88. Moreaux J., Cremer F.W., Reme T., et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106:1021-1030.
89. Scholz J.L., Crowley J.E., Tomayko M.M., et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 2008, 105:15517-15522.
90. Mitchison N.A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955, 102:157-177.
91. Di Rosa F., Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med 1996, 183:2153-2163.
92. Brandle D., Joergensen J., Zenke G., Burki K., Hof R.P. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 1998, 65:1489-1493.
93. Moulin V., Andris F., Thielemans K., Maliszewski C., Urbain J., Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000, 192:475-482.
94. Vongwiwatana A., Tasanarong A., Hidalgo L.G., Halloran P.F. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003, 196:197-218.
95. Wasowska B.A., Qian Z., Cangello D.L., et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001, 71:727-736.
96. Noorchashm H., Reed A.J., Rostami S.Y., et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006, 177:7715-7722.
97. Ng Y.H., Li Q., Marlowe A., Hoffman R., Chalasani G. Antigen presentation by B cells promotes heart allograft rejection and development of alloreactive memory T cells. Am J Transplant 2008, 8(Suppl 2):177-336.
98. Burns A.M., Ma L., Li Y., et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J Immunol 2009, 182:1314-1324.
99. Fan X., Ang A., Pollock-Barziv S.M., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004, 10:1227-1233.
100. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115:2914-2923.
101. Yada A., Ebihara S., Matsumura K., et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol 2003, 225:21-32.
102. Parsons R.F., Vivek K., Redfield R.R., et al. B-cell tolerance in transplantation: is repertoire remodeling the answer?. Expert Rev Clin Immunol 2009, 5:703-723.
103. Kwun J., Knechtle S.J. Overcoming chronic rejection-can it B?. Transplantation 2009, 88:955-961.
104. West L.J. B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 2006, 81:301-307.
105. Liu C., Noorchashm H., Sutter J.A., et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007, 13:1295-1298.
106. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step by step towards immune competence. Trends Immunol 2003, 24:343-349.
107. Clatworthy M.R., Watson C.J., Plotnek G., et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009, 360:2683-2685.
108. Deeks E.D., Keating G.M. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009, 69:1483-1512.
109. Hamilton A., Gallipoli P., Nicholson E., Holyoake T.L. Targeted therapy in haematological malignancies. J Pathol 2010, 220:404-418.
110. Ryan M.C., Grewal I.S. Targeting of BAFF and APRIL for autoimmunity and oncology. Adv Exp Med Biol 2009, 647:52-63.
111. Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006, 77:3-11.
112. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700-703.
113. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006, 54:723-732.
114. Pers J.O., Devauchelle V., Daridon C., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
115. Zarkhin V., Li L., Sarwal M.M. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 2009, 88:1229-1230.
116. Sundberg A., Samaniego M., Pirsch J., et al. A pilot study of Campath-1H and rituximab induction therapy combined with CellCept to allow for a calcineurin inhibitor-free regimen after renal transplantation. Am J Transplant 2009, 9(Suppl 2):1-766.
117. Bloom D.D.P.K., Chang Z., et al. BAFF dysregulation in renal transplant patients treated with campath-1H. Am J Transplant 2009, 9(Suppl 2):1-766.
118. Bloom D., Chang Z., Pauly K., et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009, 9:1835-1845.
119. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358:353-361.
120. Porcheray F., Wong W., Saidman S.L., et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 2009, 9:2126-2135.
121. Xu H., He X., Liu Q., et al. The abnormal high expression of B cell activating factor belonging to TNF superfamily (BAFF) and its potential role in kidney transplant recipients. Cell Mol Immunol 2008, 5:465-470.
122. Xu H., He X., Liu Q., et al. Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc 2009, 41:1552-1556.
123. Chung J.B., Wells A.D., Adler S., Jacob A., Turka L.A., Monroe J.G. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness. J Immunol 2003, 171:1758-1767.
124. Tarlinton D.M., Batista F., Smith K.G. The B-cell response to protein antigens in immunity and transplantation. Transplantation 2008, 85:1698-1704.
125. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
126. Chevrier S., Genton C., Kallies A., et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci U S A 2009, 106:3895-3900.
127. Hu C.Y., Rodriguez-Pinto D., Du W., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007, 117:3857-3867.
128. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
129. Becker Y.T., Samaniego-Picota M., Sollinger H.W. The emerging role of rituximab in organ transplantation. Transpl Int 2006, 19:621-628.
130. Pescovitz M.D. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin Transplant 2006, 20:48-54.
131. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
132. Sarwal M., Chua M.S., Kambham N., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003, 349:125-138.
133. Tsai E.W., Rianthavorn P., Gjertson D.W., Wallace W.D., Reed E.F., Ettenger R.B. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006, 82:1769-1773.
134. Hippen B.E., DeMattos A., Cook W.J., Kew C.E., Gaston R.S. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005, 5:2248-2252.
135. Martins H.L., Silva C., Martini D., Noronha I.L. Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens. Transplant Proc 2007, 39:432-434.
136. Zarkhin V., Li L., Kambham N., Sigdel T., Salvatierra O., Sarwal M.M. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008, 8:2607-2617.
137. Zarkhin V., Kambham N., Li L., et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008, 74:664-673.
138. Pescovitz M.D. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr Transplant 2004, 8:9-21.
139. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74.
140. Faguer S., Kamar N., Guilbeaud-Frugier C., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007, 83:1277-1280.
141. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
142. Trivedi H.L., Terasaki P.I., Feroz A., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87:1555-1561.
143. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.
144. Doxiadis I.I., Duquesnoy R.J., Claas F.H. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005, 17:536-540.
145. Beimler J.H., Susal C., Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 2006, 20(Suppl 17):7-12.
146. Doxiadis I.I., Claas F.H. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr Opin Organ Transplant 2009, 14:410-413.
147. Haririan A., Nogueira J., Kukuruga D., et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009, 9:536-542.
148. DiMichele D.M., Kroner B.L. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002, 87:52-57.
149. Kempton C.L., White G.C. How we treat a hemophilia a patient with a factor VIII inhibitor. Blood 2009, 113:11-17.
150. Nilsson I.M., Berntorp E., Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988, 318:947-950.
151. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003, 3:1017-1023.
152. Beimler J.H., Morath C., Schmidt J., et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009, 87:668-671.
153. Tanriover B., Wright S.E., Foster S.V., et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc 2008, 40:3393-3396.
154. Ravichandran P., Natrajan T., Jaganathan R. Combination treatment of low dose anti-thymocyte globulin (ATG), rituximab and high dose sirolimus as induction agents in immune-conditioned recipients. Int Immunopharmacol 2006, 6:1973-1976.
155. Tanabe K., Ishida H., Shimizu T., Omoto K., Shirakawa H., Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. a comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009, 162:61-74.
156. Genberg H., Kumlien G., Wennberg L., Berg U., Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008, 85:1745-1754.
157. Yoon H.E., Hyoung B.J., Hwang H.S., et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci 2009, 24(Suppl):S148-S155.
158. Munoz A.S., Rioveros A.A., Cabanayan-Casasola C.B., Danguilan R.A., Ona E.T. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008, 40:2218-2221.
159. Amante A.J., Ejercito R. Management of highly sensitized patients: capitol medical center experience. Transplant Proc 2008, 40:2274-2280.
160. Ignjatovic L., Kovacevic Z., Jovanovic D., et al. Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kidney recipients. Vojnosanit Pregl 2009, 66:117-122.
161. Reinsmoen N.L., Lai C.H., Vo A., et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008, 86:820-825.
162. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004, 77:542-548.
163. Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
164. Tak P.P., Thurlings R.M., Rossier C., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
165. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
166. Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 2008, 9:1216-1227.
167. Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009, 37:89-99.
168. Bracewell C., Isaacs J.D., Emery P., Ng W.F. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009, 9:909-919.
169. Dall'Era M., Chakravarty E., Wallace D., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
170. Boskovic S., Smith N.R., Kawai T., et al. Inhibitory effects of atacicept (TACI-Ig) on circulating antibodies, B cells and plasma cells in allosensitized cynomolgous monkeys. Am J Transplant 2008, 8(Suppl 2):177-336.
171. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136:26-36.
172. Harris A., Krams S.M., Martinez O.M. MicroRNAs as immune regulators: implications for transplantation. Am J Transplant 2010, 10:713-719.
173. Xiao C., Calado D.P., Galler G., et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
174. Zhou B., Wang S., Mayr C., Bartel D.P., Lodish H.F. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 2007, 104:7080-7085.
175. Thai T.H., Calado D.P., Casola S., et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
176. Krutzfeldt J., Rajewsky N., Braich R., et al. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438:685-689.
177. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009, 10:578-585.
178. Anglicheau D., Sharma V.K., Ding R., et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009, 106:5330-5335.